FDA Rejects Summit Therapeutics' Lung Cancer Drug Until It Proves Survival Benefit
Biotech·November 16, 2026
Summit Therapeutics has suffered a major setback in its push to bring its lung cancer drug to market. The U.S. Food and Drug Administration declined to approve the treatment, telling the company it needs to demonstrate that the drug helps people live longer, not only that it slows the growth of tumors.
The drug has been one of the most closely watched experimental cancer therapies in biotech for several years. Investors and analysts have followed its development closely, so a refusal at this stage puts Summit's timeline and its outlook under fresh scrutiny.
The sticking point is overall survival. Regulators generally expect new cancer treatments to extend life, and progression-free survival, the time before a tumor starts growing again, is usually treated as a useful but incomplete measure. Summit's earlier results pointed to benefits on that progression measure. The agency's message is that the survival evidence is not yet strong enough to support approval.
Closing that gap typically means waiting for trial data to mature or running additional studies, which can take years and cost a great deal. How quickly Summit can respond, and whether the decision changes its financing or partnership plans, will depend on what the company disclosed to investors and what it plans to submit next.
The episode also serves as a reminder that the FDA continues to hold cancer drugs to a high bar on survival, even when earlier endpoints look promising. Other developers working on novel immunotherapy combinations will be watching how the agency handles this application.
Reporting based on an external source.